Clinical Trial

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes found in the majority of DIPG and DMG tumors. Newly diagnosed patients with DIPG and DMG who have completed radiation six to ten weeks prior to enrollment are eligible.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2021-06-21; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2022-01-10
Trial Details
NCT Number NCT04943848
Lead Sponsor Ann & Robert H Lurie Children's Hospital of Chicago
Collaborators: Dana-Farber Cancer Institute, Children's Hospital of Orange County, University of Calgary
Conditions Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Enrollment 36 participants
Start Date 2022-01-10
Primary Completion 2026-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-17